ATA - NOV 7, 2017 - The American Thyroid Association (ATA) has long been an advocate for the use of potassium iodide (KI) as a thyroid blocking agent in the event of a nuclear accident (1). In 2002, the ATA issued a statement on the use of KI in the event of a nuclear power plant accident that was co-endorsed by the American Association of Clinical Endocrinologists, the Lawson Wilkins Pediatric Endocrine Society, and the Thyroid Foundation of America (2). Since then, there are new data in the aftermath of the release of radioactive iodine (131I) from the Fukushima nuclear reactors (3); the National Academy of Sciences’ 2004 report on KI use (4); evolving policies in the United States and internationally; and many peer reviewed publications (5), including updated data from the Chernobyl accident. In this statement, ‘‘predistribution’’ is referred to as the supply of KI directly to individuals in the general population within a defined area surrounding an operating nuclear power plant. Presumably, in all cases, KI will also be available (i.e., stockpiled) within the same area. ‘‘Stockpiling’’ is defined as the availability of KI at key locations sufficient to protect the local population, such as schools, hospitals, clinics, post offices, pharmacies, and police and fire stations within a larger defined area around an operating nuclear facility. Included in this term is inclusion of KI in the U.S. Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) (6) and similar programs. READ FULL STATEMENT (PDF)
Nuclear radiation blocking drug for civilian distribution part of 14 Million tablet order May 13, 2014 – Nukepills.com announced today that the U.S. Department of Health and Human Services (HHS) was recently shipped 6,383,000 tablets of FDA approved potassium iodide for protection against radiation in the event of a nuclear reactor accident. The balance of the total 14 million tablet solicitation by HHS, on behalf of the Nuclear Regulatory Commission (NRC), is scheduled for delivery by the end of 2014. Limited Distribution Distribution of the potassium iodide is limited to only a few tablets for each U.S. resident that lives within the NRC’s 10-mile Emergency Planning Zone around U.S. nuclear reactors. However, the American Thyroid Association states “Potassium iodide should be made available to populations living within 200 miles of a nuclear power plant.” All U.S. residents that wish to safeguard against potential U.S. nuclear reactor disasters may purchase a full 14-day supply of potassium iodide, no prescription necessary, directly at Nukepills.com. What is Potassium Iodide? In 1982 the FDA approved potassium iodide tablets as a thyroid-blocking agent for radiation exposure. In the event of nuclear disasters such as Fukushima and Chernobyl or fallout from a nuclear bomb, radioactive iodine (I-131), the predominant radionuclide created by nuclear fission, can travel thousands of miles downwind and cause thyroid cancer. The thyroid is the only organ that absorbs, stores and uses iodine. Potassium iodide, if stockpiled and administered daily as needed, can prevent the thyroid’s absorption of the radioactive iodine by saturating the thyroid with safe, stable iodine. About Nukepills Nukepills.com, founded in 1999, supplies radiation emergency products to the general public, pharmacies, hospitals, nuclear facilities, and governments at the local, state, federal and international level. Other radiation emergency supplies include personal radiation detectors and radiation emergency kits offered domestically and internationally, retail and wholesale. In 2009 Nukepills sold 5.4 million doses of FDA approved potassium iodide to Kuwait’s Ministry of Health. In 2011 the company donated and delivered over 50,000 potassium iodide tablets to Japan within days after the Fukushima Daiichi nuclear disaster.